Table 2.

Results of some of the recent clinical experience with Mammosite Brachytherapy System with more than a year follow up.

Author	No of cases	Median follow up interval(months)	IBF	Good/Excellent cosmesis
Benitez et al.[73]	43	65	0%	81.3%
Niehoff et al [69]	11	20	0%	n/a
Patel et al.[75]	26	48.5	0%	n/a
Vicini et al.[71]	1440	30	1.6%	95%
Chen et al.[76]	70	26.1	5.7%	n/a
Belkacemi et al. [77]	25	13	0%	84%
Voth et al.[78]	55	24	3.6%	n/a
Dragun et al. [70]	90	24	2.2%	90%
Vicini et al.[79]	1440	60	2.6%	90.6%
Jeruss et al. [74]	194$	54.4	3.1%	92%

n/a data not available, IBF = ipsilateral breast failure, $ these are ductal carcinoma in situ (DCIS) patients recruited in the American Society of Breast Surgeons APBI registry trial